Immunocine

Research

Since its discovery in 2006, the IDCT Protocol has undergone continual research and clinical trials.

Immunocine’s Associated Publications

Our Immunotherapy Protocol was first discovered in 2006 within the prestigious Texas Medical Center. This research has continued and has ultimately resulted in active clinical trials studying the treatment of Glioblastoma and Pancreatic Ductal Adenocarcinoma.

The following research is specific to Immunocine's unique Dendritic Cell Treatment, which is patented and the first of its kind. These publications provide both scientific validation of our Immunotherapy as well as review the treatment's pre-clinical and clinical successes.

The Immunocine Team recommends starting with the following four papers to develop a better mechanistic understanding of our treatment protocol and review both pre-clinical and clinical successes.

In this seminal publication, it was discovered and demonstrated that Dendritic Cells possess a never-before-seen intrinsic mechanism critical to appropriate immunity. This mechanism essentially allows for the Dendritic Cell to “sense” the internal and external cellular environments simultaneously to determine if a Th1 Killer T cell response is appropriate and necessary (the type of immune response needed to eliminate viruses and cancers).

This phenomenon is demonstrated down to the MHC binding peptide level and is validated by a variety of measures including decreased CTLA-4 expression, increased CD83 levels, and increased IL-12 and Interferon—secretion by the Dendritic Cells and responding T cells, respectively.

Taken together, it is apparent the Dendritic Cells possess a very detailed and important mechanism never previously identified and potentially critical to optimal immune responsiveness.

Content Will Be Changed later

Start Your Personalized Treatment

1) Apply to See If You Qualify

If you meet the minimum requirements outlined above and are interested in seeing how our treatment could work for your specific case, please submit your info on our submission form or call us directly at +1 (888) 575-2572.

2) Schedule an Intro Call

Our team loves discussing our treatment with potential patients. We will schedule an intro call to learn about your diagnosis and answer any questions that you may have. Prior to the call, we will share additional info for you to review with your family and physician as you see fit.

3) Undergo Medical Evaluation

After confirming your eligibility, our Medical Team will perform a complimentary medical evaluation. This includes a questionnaire and review of your medical records. Once complete, you can be approved for treatment and we can build a personalized treatment program for you.

Get Started

Since its discovery in 2006, the IDCT Protocol has undergone continual research and clinical trials.

Th-1 Polarization Is Regulated by Dendritic Cell Comparison of MHC Class I and Class II Antigens Decker WK, Xing D, Li S, et al. Blood. Published January 2009.

MHC class I and II peptide homology regulates the cellular immune response Halpert MM, Konduri V, Liang D, et al. Faseb. Published April 2020.

Chemo-immunotherapy mediates durable cure of orthotopic KrasG12D/p53-/- pancreatic ductal adenocarcinoma. Konduri V, Li D, Halpert MM, et al. Oncoimmunology. Published July 2016.

A retrospective analysis comparing APCEDEN dendritic cell immunotherapy with best supportive care in refractory cancer. Kumar C, Kohli S, Chiliveru S, et al. Immunotherapy. Published September 2017.

Start Your Personalized Treatment

1) Apply to See If You Qualify

2) Schedule an Intro Call

3) Undergo Medical Evaluation